Teacher Retirement System of Texas bought a new stake in Aerie Pharmaceuticals Inc (NASDAQ:AERI) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 10,334 shares of the company’s stock, valued at approximately $617,000.
Other institutional investors and hedge funds have also made changes to their positions in the company. Moody Aldrich Partners LLC acquired a new position in shares of Aerie Pharmaceuticals in the 3rd quarter valued at approximately $1,046,000. Wells Fargo & Company MN raised its position in shares of Aerie Pharmaceuticals by 9.2% in the 3rd quarter. Wells Fargo & Company MN now owns 26,898 shares of the company’s stock valued at $1,308,000 after purchasing an additional 2,266 shares in the last quarter. Swiss National Bank raised its position in shares of Aerie Pharmaceuticals by 7.5% in the 3rd quarter. Swiss National Bank now owns 50,300 shares of the company’s stock valued at $2,445,000 after purchasing an additional 3,500 shares in the last quarter. Rhumbline Advisers raised its position in shares of Aerie Pharmaceuticals by 5.0% in the 3rd quarter. Rhumbline Advisers now owns 36,645 shares of the company’s stock valued at $1,781,000 after purchasing an additional 1,732 shares in the last quarter. Finally, Iguana Healthcare Management LLC raised its position in shares of Aerie Pharmaceuticals by 5.3% in the 3rd quarter. Iguana Healthcare Management LLC now owns 100,000 shares of the company’s stock valued at $4,860,000 after purchasing an additional 5,000 shares in the last quarter. 96.94% of the stock is currently owned by institutional investors.
A number of brokerages have issued reports on AERI. HC Wainwright set a $78.00 target price on Aerie Pharmaceuticals and gave the company a “buy” rating in a research report on Thursday, March 1st. Seaport Global Securities reiterated a “buy” rating on shares of Aerie Pharmaceuticals in a report on Monday, March 5th. Canaccord Genuity boosted their price target on Aerie Pharmaceuticals from $73.00 to $86.00 and gave the company a “buy” rating in a report on Thursday, January 25th. BidaskClub upgraded Aerie Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, March 6th. Finally, Cantor Fitzgerald set a $86.00 price target on Aerie Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, February 28th. Three research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $78.75.
Aerie Pharmaceuticals (NASDAQ:AERI) last issued its quarterly earnings data on Wednesday, February 28th. The company reported ($1.38) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.21) by ($0.17). equities analysts predict that Aerie Pharmaceuticals Inc will post -3.62 earnings per share for the current fiscal year.
WARNING: This piece was first published by Markets Daily and is the property of of Markets Daily. If you are reading this piece on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark laws. The legal version of this piece can be accessed at https://www.themarketsdaily.com/2018/03/12/teacher-retirement-system-of-texas-invests-617000-in-aerie-pharmaceuticals-inc-aeri.html.
About Aerie Pharmaceuticals
Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).
Want to see what other hedge funds are holding AERI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aerie Pharmaceuticals Inc (NASDAQ:AERI).
Receive News & Ratings for Aerie Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.